{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:15:27Z","timestamp":1769606127024,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2008,10,18]],"date-time":"2008-10-18T00:00:00Z","timestamp":1224288000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s10557-008-6143-6","type":"journal-article","created":{"date-parts":[[2008,10,17]],"date-time":"2008-10-17T17:33:14Z","timestamp":1224264794000},"page":"161-170","source":"Crossref","is-referenced-by-count":21,"title":["Secondary Prevention of Coronary Disease with ACE Inhibition-does Blood Pressure Reduction with Perindopril Explain the Benefits in EUROPA?"],"prefix":"10.1007","volume":"23","author":[{"given":"Willem J.","family":"Remme","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaap W.","family":"Deckers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim M.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten L.","family":"Simoons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"EUROPA Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,18]]},"reference":[{"key":"6143_CR1","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1161\/01.CIR.90.4.1731","volume":"90","author":"JD Rutherford","year":"1994","unstructured":"Rutherford JD, Pfeffer MA, Moye LA, Davis BR, Flaker GC, Kowey PR, et al. Effects of captopril on ischemic events after myocardial infarction. Results of the survival and ventricular enlargement trial. Circulation 1994;90:1731\u20138.","journal-title":"Circulation"},{"key":"6143_CR2","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/0140-6736(92)92889-N","volume":"340","author":"S Yusuf","year":"1992","unstructured":"Yusuf S, Pepine CJ, Garces C, Pouler H, Salem D, Kostis J, et al. Effects of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173\u20138.","journal-title":"Lancet"},{"key":"6143_CR3","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/hc3001.093502","volume":"104","author":"GR Dagenais","year":"2001","unstructured":"Dagenais GR, Yusuf S, Bourassa MG, Yi Q, Bosch J, Lonn EM, et al. Effects of ramipril on coronary events in high-risk persons. Results of the heart outcomes prevention evaluation study. Circulation 2001;104:522\u20136.","journal-title":"Circulation"},{"key":"6143_CR4","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","volume":"362","author":"The European Reduction Of cardiac events with Perindopril in stable coronary Artery disease Investigators","year":"2003","unstructured":"The European Reduction Of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled multicentre trial (EUROPA). Lancet 2003;362:782\u20138.","journal-title":"Lancet"},{"key":"6143_CR5","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0140-6736(00)02327-8","volume":"355","author":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration","year":"2000","unstructured":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000;355:1955\u201364.","journal-title":"Lancet"},{"key":"6143_CR6","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(01)06411-X","volume":"358","author":"JA Staessen","year":"2001","unstructured":"Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001;358:1305\u201315.","journal-title":"Lancet"},{"key":"6143_CR7","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1097\/00004872-200306000-00002","volume":"21","author":"JA Staessen","year":"2003","unstructured":"Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003;21:1055\u201376.","journal-title":"J Hypertens"},{"key":"6143_CR8","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","volume":"362","author":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration","year":"2003","unstructured":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 2003;362:1527\u201335.","journal-title":"Lancet"},{"key":"6143_CR9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1023\/A:1015709617405","volume":"16","author":"VJ Dzau","year":"2002","unstructured":"Dzau VJ, Bernstein K, Celermajer D, Cohen J, Dahlof B, Deanfield J, et al. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther 2002;16:149\u201360.","journal-title":"Cardiovasc Drugs Ther"},{"key":"6143_CR10","doi-asserted-by":"crossref","first-page":"J16","DOI":"10.1053\/euhj.1997.0797","volume":"19","author":"WJ Remme","year":"1998","unstructured":"Remme WJ. Effect of ACE inhibition on neurohormones. Eur Heart J 1998;19:J16\u201323.","journal-title":"Eur Heart J"},{"key":"6143_CR11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1023\/A:1011131130922","volume":"15","author":"Gomma AH, Fox KM. for the EUROPA investigators","year":"2001","unstructured":"Gomma AH, Fox KM. for the EUROPA investigators. The EUROPA trial: design, baseline demography and status of the substudies. Cardiovasc Drugs Ther 2001;15:169\u201379.","journal-title":"Cardiovasc Drugs Ther"},{"key":"6143_CR12","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","volume":"289","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The JNC7 report. JAMA 2003;289:2560\u201372.","journal-title":"JAMA"},{"key":"6143_CR13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"The Heart Outcomes Prevention Evaluation Study Investigators","year":"2000","unstructured":"The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145\u201353.","journal-title":"N Engl J Med"},{"key":"6143_CR14","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","volume":"358","author":"PROGRESS Collaborative Group","year":"2001","unstructured":"PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033\u201341.","journal-title":"Lancet"},{"key":"6143_CR15","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1161\/01.HYP.0000174591.42889.a2","volume":"46","author":"P Verdecchia","year":"2005","unstructured":"Verdecchia P, Reboldi G, Angeli F, Gattobigio R, Bentivoglio M, Thijs L, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005;46:386\u201392.","journal-title":"Hypertension"},{"key":"6143_CR16","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/HJH.0b013e3280bad9b4","volume":"25","author":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration","year":"2007","unstructured":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration. Blood pressure-dependent and independent effects of agents that inhibit the renin\u2013angiotensin system. J Hypertens 2007;25:951\u20138.","journal-title":"J Hypertens"},{"key":"6143_CR17","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/S0140-6736(01)07186-0","volume":"358","author":"P Sleight","year":"2001","unstructured":"Sleight P, Yusuf S, Pogue J, Tsuyuki R, Diaz R, Probstfield J, Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet 2001;358:2130\u20131.","journal-title":"Lancet"},{"key":"6143_CR18","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(04)16980-8","volume":"364","author":"PA Poole-Wilson","year":"2004","unstructured":"Poole-Wilson PA, Lubsen J, Kirwan BA, Van Dalen FJ, Wagener G, Danchin N, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004;364:849\u201357.","journal-title":"Lancet"},{"key":"6143_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2007.07.061","volume":"577","author":"C Ceconi","year":"2007","unstructured":"Ceconi C, Francolini G, Olivares A, Comini L, Bachetti T, Ferrari R. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol 2007;577:1\u20136.","journal-title":"Eur J Pharmacol"},{"key":"6143_CR20","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/hy0202.103417","volume":"39","author":"JL Zhuo","year":"2002","unstructured":"Zhuo JL, Mendelsohn FAO, Ohishi M. Perindopril alters vascular angiotensin-converting enzyme, AT1 receptor and nitric oxide synthase expression in patients with coronary artery disease. Hypertension 2002;39:634\u20138.","journal-title":"Hypertension"},{"key":"6143_CR21","first-page":"923","volume":"20","author":"JZ Su","year":"1999","unstructured":"Su JZ, Chen SC, Wu KG, Chen DG, Rui HB, Wang XY, et al. Effects of perindopril, propranolol and dihydrochlorothiazide on cardiovascular remodeling in spontaneously hypertensive rats. Zhongguo-Yao-Li-Xue-Bao 1999;20:923\u20138.","journal-title":"Zhongguo-Yao-Li-Xue-Bao"},{"key":"6143_CR22","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10557-007-6068-5","volume":"21","author":"C Ceconi","year":"2007","unstructured":"Ceconi C, Francolini G, Bastianon D, Gitti GL, Comini L, Ferrari R. Differences in the effect of angiotensin-converting enzyme inhibitors on the rate on the rate of endothelial cell apoptosis: in vitro and in vivo studies. Cardiovasc Drugs Ther 2007;21:423\u20139.","journal-title":"Cardiovasc Drugs Ther"},{"key":"6143_CR23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s10557-007-6071-x","volume":"21","author":"WJ Remme","year":"2007","unstructured":"Remme WJ. Secondary prevention of coronary artery disease and the choice of the ACE inhibitor\u2014why EUROPA and not PEACE. Cardiovasc Drugs Ther 2007;21:405\u20139.","journal-title":"Cardiovasc Drugs Ther"},{"key":"6143_CR24","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.CIR.0000021122.63813.32","volume":"106","author":"R Candido","year":"2002","unstructured":"Candido R, Jandeleit-Dahm KA, Cao Z, Nesteroff SP, Burns WC, Twigg SM, et al. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 2002;106:246\u201353.","journal-title":"Circulation"},{"key":"6143_CR25","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1440-1681.1996.tb03038.x","volume":"23","author":"PA Fennessy","year":"1996","unstructured":"Fennessy PA, Campbell JH, Mendelsohn FA, Campbell GR. Angiotensin-converting enzyme inhibitors and atherosclerosis: relevance of animal models to human disease. Clin Exp Pharmacol Physiol 1996;23:530\u20132.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"6143_CR26","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1161\/01.HYP.37.2.270","volume":"37","author":"K Matsumoto","year":"2001","unstructured":"Matsumoto K, Morishita R, Moriguchi A, Tomita N, Aoki M, Sakonjo H, et al. Inhibition of neointima by angiotensin-converting enzyme inhibitor in porcine coronary artery balloon-injury model. Hypertension 2001;37:270\u20134.","journal-title":"Hypertension"},{"key":"6143_CR27","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1161\/01.CIR.94.12.3115","volume":"94","author":"I Antoni","year":"1996","unstructured":"Antoni I, Lerebours G, Nitenberg A. Angiotensin converting enzyme inhibition restores flow-dependent and cold-pressure test-induced dilations in coronary arteries of hypertensive patients. Circulation 1996;94:3115\u201322.","journal-title":"Circulation"},{"key":"6143_CR28","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1161\/01.HYP.0000070956.57418.22","volume":"41","author":"L Ghiadoni","year":"2003","unstructured":"Ghiadoni L, Magagna A, Versari D, Kardasz I, Huang Y, Taddei S, et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003;41:1281\u20136.","journal-title":"Hypertension"},{"key":"6143_CR29","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0735-1097(03)00162-1","volume":"41","author":"T Matsumoto","year":"2003","unstructured":"Matsumoto T, Minai K, Horie H, Ohira N, Takashima H, Tarutani Y, et al. Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients. J Am Coll Cardiol 2003;41:1373\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"6143_CR30","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cardiores.2006.10.021","volume":"73","author":"C Ceconi","year":"2007","unstructured":"Ceconi C, Fox KM, Remme WJ, Simoons ML, Bertrand M, Parrinello G, on behalf of the EUROPA Investigators, on behalf of the PERTINENT Investigators and the Statistical Committee, et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007;73:237\u201346.","journal-title":"Cardiovasc Res"},{"key":"6143_CR31","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10557-007-6041-3","volume":"21","author":"ML Bots","year":"2007","unstructured":"Bots ML, Remme WJ, Luscher TF, Fox KM, Bertrand M, Ferrari R, Grobbee, EUROPA-PERFECT Investigators, et al. ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial. Cardiovasc Drugs Ther 2007;21:269\u201379.","journal-title":"Cardiovasc Drugs Ther"},{"key":"6143_CR32","first-page":"J56","volume":"19","author":"ML Simoons","year":"1998","unstructured":"Simoons ML, Vos J, de Feyter PJ, Bots ML, Remme WJ, Grobbee DE, et al. EUROPA substudies, confirmation of pathophysiological concepts. Eur Heart J 1998;19:J56\u201360.","journal-title":"Eur Heart J"},{"key":"6143_CR33","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1161\/hy1101.099502","volume":"38","author":"P Svensson","year":"2001","unstructured":"Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures. A HOPE substudy. Hypertension 2001;38:e28\u201332.","journal-title":"Hypertension"},{"key":"6143_CR34","first-page":"1191","volume":"12","author":"MG Myers","year":"1996","unstructured":"Myers MG, on behalf of the Perindopril Multicentre Dose-Response Study Group. A dose-response study of perindopril in hypertension: effects on blood pressure 6 and 24\u00a0H after dosing. Can J Cardiol 1996;12:1191\u20136.","journal-title":"Can J Cardiol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-008-6143-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-008-6143-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-008-6143-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T17:28:03Z","timestamp":1559237283000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-008-6143-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,18]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["6143"],"URL":"https:\/\/doi.org\/10.1007\/s10557-008-6143-6","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,18]]}}}